$0.19
(29.23%)
Add to watchlist
Create an alert
Stocks and Shares ISASalarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Company Information
About this company
Key people
Frederick E. Pierce
Chief Executive Officer, Director
Mark J. Rosenblum
Chief Financial Officer, Executive Vice President
Barbara Hibner
Chief Scientific Officer
Peter Marschel
Chief Business Officer
William K. McVicar
Independent Chairman of the Board
David J. Arthur
Director
Tess Burleson
Independent Director
Arnold C. Hanish
Independent Director
Paul I. Lammers
Independent Director
Click to see more
Key facts
- Shares in issue5.86m
- EPICSLRX
- ISINUS79400X5032
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.14m
- Employees2
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.